Sign in

You're signed outSign in or to get full access.

Michael Obadiah

Research Analyst at H.C. Wainwright

Michael Obadiah is an equity research analyst at H.C. Wainwright, specializing in biotechnology and life sciences coverage. He regularly covers companies such as Anavex Life Sciences, Arrowhead Pharmaceuticals, and uniQure, focusing on emerging therapies and clinical developments in neurology and rare diseases. Obadiah frequently represents H.C. Wainwright in high-level earnings calls and investor briefings for these firms, demonstrating active involvement in the sector, although publicly available records do not provide detailed performance metrics, rankings, or prior career history. Professional licensing information and notable external recognitions are not currently documented in public databases.

Michael Obadiah's questions to ANAVEX LIFE SCIENCES (AVXL) leadership

Question · Q4 2025

Michael Obadiah asked about the potential commercial impact of semaglutide's failure on Blarcamesine in Alzheimer's disease, the timeline for the next formal discussion of Blarcamesine with the FDA, and Anavex's near-term initiatives for Blarcamesine approval in regions beyond the European Union and the United States.

Answer

President and CEO Christopher Missling explained that semaglutide's setback underscores the complexity of Alzheimer's and the unmet medical need. He highlighted Blarcamesine's upstream mechanism, which restores autophagy, and its clinically meaningful efficacy in slowing cognitive decline (over 50% in some cases) with an acceptable safety profile (no ARIA) in the phase 2b/3 study. Regarding the FDA, he stated that updates on initial discussions would be provided as they become available. For global approvals, Anavex is exploring other regulatory geographies and addressing open questions.

Ask follow-up questions

Fintool

Fintool can predict ANAVEX LIFE SCIENCES logo AVXL's earnings beat/miss a week before the call

Question · Q4 2025

Michael Obadiah from HC Wainwright asked about the likely commercial impact of semaglutide's failure on Blarcamesine's outlook in Alzheimer's disease, the timing of the next formal FDA discussion for Blarcamesine, and Anavex's near-term initiatives for Blarcamesine approval in regions beyond the European Union and the United States.

Answer

President and CEO Christopher Missling explained that semaglutide's setback highlights the complexity of Alzheimer's disease, underscoring the unmet need and Blarcamesine's differentiated upstream mechanism, clinically meaningful efficacy, and acceptable safety profile. He stated that updates on FDA discussions would be provided as they become available and that Anavex is actively exploring other regulatory geographies for approval.

Ask follow-up questions

Fintool

Fintool can write a report on ANAVEX LIFE SCIENCES logo AVXL's next earnings in your company's style and formatting